Dual Checkpoint Blockade Takes Aim at Relapsed Mesothelioma.
In the largest clinical trial to date of immune checkpoint inhibitors for mesothelioma, patients treated with nivolumab-either alone or in combination with ipilimumab-posted impressive response rates and survival outcomes, according to data presented at the 2017 American Society of Clinical Oncology Annual Meeting. However, the combination, although more effective, was also more toxic.